Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Premium Light Street’s October Gain Puts the Fund in Reach of Its High-Water Mark Stephen Taub BlackRock Says Hedge Funds Are Key as Diversification Falters in Volatile Markets Julie Segal The Shifting Value Dynamics Between Winter Wheats Sponsored by CME Group